Spectrum Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Spectrum Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count).
Spectrum Pharmaceuticals: 52 sponsored US clinical trials, 1 recruiting.
Spectrum Pharmaceuticals sponsors 52 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 28 completed. 16 of these trials are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Phosphate Binding Capacity, with 1 trials.
Top-decile sponsor footprint
Spectrum Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
28 of 51 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (54.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
52 total, page 2 of 2
Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
NCT00005887
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00004202
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 20 |
| Phase 3 | 16 |
What is open in the Spectrum Pharmaceuticals pipeline
1 recruiting of 52 indexed (2% open); 28 completed (54%).
Phase mix: 16 late (III/IV) vs 36 early (I/II) (early-phase heavy).
Top condition: Phosphate Binding Capacity (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Spectrum Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 52 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Spectrum Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 52 trials (± recruiting share)
- Albany Medical College · 52 trials · 13% recruiting
- Burzynski Research Institute · 52 trials · 0% recruiting
- Dr. Reddy's Laboratories Limited · 52 trials · 0% recruiting
- PTC Therapeutics · 52 trials · 2% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Société des Produits Nestlé (SPN) · 2% recruiting · 53 trials
- Sanofi Pasteur, a Sanofi Company · 2% recruiting · 153 trials
- Carelon Research · 2% recruiting · 50 trials
- Alcon Research · 2% recruiting · 275 trials
Related
What to do with this Spectrum Pharmaceuticals page
52 registered trials is a research-attention snapshot, not an endorsement of Spectrum Pharmaceuticals or any single study.
- 1 of Spectrum Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Phosphate Binding Capacity is the condition Spectrum Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Phosphate Binding Capacity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Spectrum Pharmaceuticals pipeline card: 52 registered trials from official public datasets.Report a data error.